대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Optimal dose of thymoglobulin for induction therapy in high risk kidney transplant recipients
저자	Yaerim Kim* 1, 2, Hayeon Park1, 2, Sang Mok Yeo1, 2, Seong Sik Kang1, 2, Woo Yeong Park1, 2, Kyubok Jin1, 2, Sung Bae Park1, 2, Juyoung Yi3, Seungyeup Han1, 2
출판정보	2016; 2016(1):
키워드	Immunosuppressive agent, Kidney Transplantation, Thymoglobulin
초록	Background: Thymoglobulin has been used for induction therapy to prevent acute rejection and delayed graft function(DGF) in kidney transplant patients. However, the usual dose of thymoglobulin is considered to be related with frequent infection. We compared the efficacy and safety of low dose thymoglobulin to high dose in high risk recipients with kidney transplantation. Methods: Twenty-one kidney transplant patients underwent induction treatment with thymoglobulin in Keimyung university Dongsan hospital and they were divided into two groups : the patients who treated with low dose thymoglobulin(<6.0g/kg) and high dose(≥6.0g/kg). All patients who included in our study have one or more risk factors for acute rejection or DGF. The risk factors were re-transplantation, recipient or donor age over 60, human leukocyte antigen(HLA) full mismatch and panel-reactive antibody(PRA) more than 50%. We compared incidence of acute rejection, infection, hematologic complications and graft survival between two groups. Results: The demographic characteristics of two groups were comparable. Mean follow up duration was 11.9±4.3 months, cumulative thymoglobulin dosage was 6.3±1.6g/kg. The incidence rates of acute antibody mediated rejection(AMR), DGF and infectious events as cytomegalovirus disease or urinary tract infection were not significantly different between two groups. Neutropenia occurred more frequently in high dose thymoglobulin group, but there was no statistically significant difference. The rate of graft loss were similar between two groups. Conclusion: There were no differences in graft survival, infectious disease and hematologic problem between two groups. We can suggest to lower the dose of thymoglobulin less than 6 g/kg for prevent acute AMR and DGF in high risk patients.
원문(PDF)	PDF 원문보기

목록

위로가기